{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-003510","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2022-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.661991+00:00","generated_at":"2026-06-26T23:14:57.424245+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Crinetics appoints former Biogen commercial lead Caren Deardorf to board","bullets":["Caren Deardorf appointed as Class II director, initial term through 2023 annual meeting.","She brings over 20 years at Biogen, led global commercial efforts for Spinraza in SMA.","Board size increased from seven to eight members to accommodate the new appointment.","Deardorf receives annual cash retainer of $40,000 plus $7,500 for committee service; granted 25,000 stock options vesting over 3 years."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-003510","json":"https://secwatch.observer/filing/0000950170-22-003510.json","markdown":"https://secwatch.observer/filing/0000950170-22-003510.md","text":"https://secwatch.observer/filing/0000950170-22-003510.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017022003510/0000950170-22-003510-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017022003510/crnx-20220311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T23:14:57.424245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9121af10db","claim":"Caren Deardorf was appointed as Director at Crinetics Pharmaceuticals, Inc..","evidence_excerpt":"the Board approved an increase in its authorized size from seven members to eight members and appointed Caren Deardorf to fill the vacancy created by such increase and serve as a Class II director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017022003510/0000950170-22-003510-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}